Drug intelligence / Profile preview

LX5051

Development stage: Preclinical
Lead developer: Lexicon Pharmaceuticals
Modality: Small Molecules

Overview

LX5051 is an SSTR3 antagonist developed by Lexicon Pharmaceuticals in collaboration with N.V. Organon for psychiatric indications. The alliance for its research, development, and potential commercialization began in September 2004.

Targets

SSTR3 (Somatostatin receptor 3)

Beyond the preview

Go deeper on LX5051.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on LX5051.

Explore the full profile